Pharmaceutical company Amgen has agreed to pay about $28 billion to buy Horizon Therapeutics, which has its U.S. headquarters in Deerfield.
FILE - This photo shows signage outside the Amgen headquarters in Thousand Oaks, Calif on Nov. 9, 2014. Amgen will acquire Horizon Therapeutics, a biopharmaceutical company that focuses on treatments for rare, autoimmune diseases, in a deal valued at approximately $26.4 billion.
Horizon, which is based in Ireland, sells orphan drugs, which are medications for rare diseases, and drugs to treat rheumatic diseases. Amgen is a large drugmaker based in California. A new Amgen subsidiary will acquire Horizon. The deal is expected to close in the first half of next year, pending regulatory approvals.Horizon has about 2,000 employees globally, including about 600 at its U.S. headquarters in Deerfield.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Horizon Therapeutics to be acquired in $28B deal, throwing future of Deerfield offices into questionHorizon sells orphan drugs, which are medications for rare diseases
Read more »
Amgen to buy Horizon Therapeutics for $26.4BAmgen Inc. announced on Monday that it will acquire Horizon Therapeutics for $26 billion to further grow the company’s medical legacy. Horizon's best-selling drug is Tepezza.
Read more »
Stocks making the biggest moves midday: Horizon Therapeutics, Coupa Software, Weber and moreThese are the stocks posting the largest moves in midday trading.
Read more »
Amgen to buy Horizon Therapeutics in $26.4B dealAmgen is spending more than $26 billion to dive deeper into rare disease treatments with the acquisition of drugmaker Horizon Therapeutics. The biotech drug developer said Monday that it will pay $116.50 in cash for each share of Horizon, which makes a treatment for thyroid eye disease that generated more than $1 billion in its first full year on the market.
Read more »
Amgen Agrees to Deal to Buy Horizon TherapeuticsThe U.S. biotech company agreed to buy drugmaker Horizon Therapeutics in a deal valued at $27.8 billion, marking the largest healthcare merger of the year.
Read more »
Amgen to buy Horizon Therapeutics in $26.4 billion dealAmgen will acquire Horizon Therapeutics, a biopharmaceutical company that focuses on treatments for rare autoimmune diseases, in a deal valued at $26.4 billion.
Read more »